Growth factor signalling in endocrine and anti-growth factor resistant breast cancer.
about
Tamoxifen-induced epigenetic silencing of oestrogen-regulated genes in anti-hormone resistant breast cancerDynamic modelling of oestrogen signalling and cell fate in breast cancer cellsModeling the estrogen receptor to growth factor receptor signaling switch in human breast cancer cellsOverexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan.Prolactin-induced mouse mammary carcinomas model estrogen resistant luminal breast cancer.New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane.Complex prolactin crosstalk in breast cancer: new therapeutic implicationsFulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptor-positive breast cancer cells to heregulin β1Activated HER-receptors in predicting outcome of ER-positive breast cancer patients treated with adjuvant endocrine therapyProteomic analysis of acquired tamoxifen resistance in MCF-7 cells reveals expression signatures associated with enhanced migration.Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance.Estrogen-mediated suppression of the gene encoding protein tyrosine phosphatase PTPRO in human breast cancer: mechanism and role in tamoxifen sensitivityDevelopment of new predictive markers for endocrine therapy and resistance in breast cancer.Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrantThe Role of BCA2 in the Endocytic Trafficking of EGFR and Significance as a Prognostic Biomarker in Cancer.Alteration of Y-box binding protein-1 expression modifies the response to endocrine therapy in estrogen receptor-positive breast cancer.PTK6 regulates growth and survival of endocrine therapy-resistant ER+ breast cancer cells.MicroRNA-335-5p and -3p synergize to inhibit estrogen receptor alpha expression and promote tamoxifen resistance.Granulosa cell tumor of the ovary after long-term use of tamoxifen and toremifene.Antihormone induced compensatory signalling in breast cancer: an adverse event in the development of endocrine resistance.Crosstalk between ERα and Receptor Tyrosine Kinase Signalling and Implications for the Development of Anti-Endocrine Resistance.
P2860
Q28481232-48F4AA6D-BB47-49F9-92EA-0ABC399CFE26Q34192940-648AE1C4-BED7-46B0-8A18-AF489FD8581BQ34367908-1F99D362-22F2-4873-A65F-079341D61B1CQ34435089-F281EEE2-A5AE-49AB-AD76-E986F0E377B3Q35029548-F762A6C3-BCD6-4392-943A-6E2DD52605A4Q35168124-BD2FA404-5FB6-4BA1-8203-FA3E040D415DQ35303180-640C7A7A-0EC0-4B45-8749-A3EE27121F8EQ35558954-B49103EE-F6C2-423B-8591-4AA39CCBA355Q36223407-F42EB88D-F957-403F-9052-652465CE77CCQ36245528-979106FC-145C-4407-8B53-D39B50FB8932Q36589865-1071BFC6-C457-4141-BBDA-1AD90FE646C9Q37106891-CB2B37CE-C10D-4E51-BB4E-CEAAFD72D715Q37157598-A5820170-26E8-4BA4-AE05-3A1696B8EDCEQ37393002-82BD5F1E-F321-4509-B1E1-E0DCEF0DD52FQ37514113-95A5F6EC-856F-47DA-9DDE-2A240D35D011Q39485529-46AE5677-BDBB-42E0-BC20-FCBD5090BA53Q45494068-D79CECDC-AC22-4F5E-A2A9-5070FAA0FE4EQ51068524-D3EC1DAC-B34F-4860-8261-EFE7994087F8Q51184967-B378D559-4326-4622-8557-A75035619424Q54610139-A74911A1-D086-4B2F-8E51-2322128EB432Q55496875-394FAB26-336D-441D-9918-6F8476451FD5
P2860
Growth factor signalling in endocrine and anti-growth factor resistant breast cancer.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Growth factor signalling in endocrine and anti-growth factor resistant breast cancer.
@ast
Growth factor signalling in endocrine and anti-growth factor resistant breast cancer.
@en
type
label
Growth factor signalling in endocrine and anti-growth factor resistant breast cancer.
@ast
Growth factor signalling in endocrine and anti-growth factor resistant breast cancer.
@en
prefLabel
Growth factor signalling in endocrine and anti-growth factor resistant breast cancer.
@ast
Growth factor signalling in endocrine and anti-growth factor resistant breast cancer.
@en
P2093
P2860
P50
P1476
Growth factor signalling in endocrine and anti-growth factor resistant breast cancer
@en
P2093
I R Hutcheson
R I Nicholson
P2860
P2888
P304
P356
10.1007/S11154-007-9033-5
P577
2007-09-01T00:00:00Z